Protein Variants | Comment | Organism |
---|---|---|
A16V | point mutation of the active site residue leads to a widespread resistance of the parasite to the drugs cycloguanil and pyrimethamine | Plasmodium falciparum |
C59R | point mutation of the active site residue leads to a widespread resistance of the parasite to the drugs cycloguanil and pyrimethamine | Plasmodium falciparum |
I164X | point mutation of the active site residue leads to a widespread resistance of the parasite to the drugs cycloguanil and pyrimethamine | Plasmodium falciparum |
N51I | point mutation of the active site residue leads to a widespread resistance of the parasite to the drugs cycloguanil and pyrimethamine | Plasmodium falciparum |
S108N | point mutation of the active site residue leads to a widespread resistance of the parasite to the drugs cycloguanil and pyrimethamine | Plasmodium falciparum |
S108T | point mutation of the active site residue leads to a widespread resistance of the parasite to the drugs cycloguanil and pyrimethamine | Plasmodium falciparum |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
Chloroquine | - |
Plasmodium falciparum | |
cycloguanil | an antifolate enzyme inhibitor used in treatment of malaria | Plasmodium falciparum | |
additional information | design and development of enzyme inhibitors based on on the bioactive conformation of WR99210 extracted from the X-ray crystal structure of quadruple mutant parasite DHFR enzyme, virtual screening and molecular docking, overview | Plasmodium falciparum | |
NCI0086195 | docking analysis, overview | Plasmodium falciparum | |
NCI0109835 | docking analysis, overview | Plasmodium falciparum | |
NCI0156252 | docking analysis, overview | Plasmodium falciparum | |
NCI0164641 | docking analysis, overview | Plasmodium falciparum | |
NCI0211175 | docking analysis, overview | Plasmodium falciparum | |
NCI0289533 | docking analysis, overview | Plasmodium falciparum | |
NCI0289541 | docking analysis, overview | Plasmodium falciparum | |
NCI0309401 | docking analysis, overview | Plasmodium falciparum | |
NCI0369769 | docking analysis, overview | Plasmodium falciparum | |
NCI0696662 | docking analysis, overview | Plasmodium falciparum | |
pyrimethamine | an antifolate enzyme inhibitor used in treatment of malaria | Plasmodium falciparum | |
WR99210 | docking analysis, overview | Plasmodium falciparum |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
7,8-dihydrofolate + NADPH + H+ | Plasmodium falciparum | - |
5,6,7,8-tetrahydrofolate + NADP+ | - |
r |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Plasmodium falciparum | - |
- |
- |
Reaction | Comment | Organism | Reaction ID |
---|---|---|---|
5,6,7,8-tetrahydrofolate + NADP+ = 7,8-dihydrofolate + NADPH + H+ | Ala16, Ile51, Cys59, Ser108 and Ile164 are active site residues | Plasmodium falciparum |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
7,8-dihydrofolate + NADPH + H+ | - |
Plasmodium falciparum | 5,6,7,8-tetrahydrofolate + NADP+ | - |
r |
Synonyms | Comment | Organism |
---|---|---|
DHFR | - |
Plasmodium falciparum |
Cofactor | Comment | Organism | Structure |
---|---|---|---|
NADP+ | - |
Plasmodium falciparum | |
NADPH | - |
Plasmodium falciparum |